Selecting the Right Cognitive Scales in Alzheimer’s Disease Trials

The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060, but treatment remains elusive. What role does selecting the right cognitive scales play in AD clinical trial success?

Download now to explore topics including:

Why picking the best endpoint is crucial
Why biomarkers are important for assessing the validity of COAs
The scales that are capable of capturing key cognitive elements of AD

For these insights and more, download the playbook.

This custom content was created by members of the studioID Expert Network for a sponsor of our publication.

studioID is PharmaVoice's award-winning content studio. We help brands tell stories that create connections, build trust, and drive demand. Learn how we can help you tell compelling stories and drive ROI. Visit studioID.com

About this email: You are receiving this message as part of your complimentary newsletter subscription to PharmaVoice. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. PharmaVoice is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550 Washington DC 20037